Advertisement
Person › Details
Pearl S. Huang (Dunad Therapeutics Ltd.)
Huang, Pearl S. (Dunad Therapeutics 202206– CEO before Cygnal Therapeutics + Roche + GSK + Merck + Beigene)
Organisation | Dunad Therapeutics Ltd. | |
Former/major organisation | Cygnal Therapeutics Inc. | |
Today | Sonata Therapeutics (US) | |
Group | Sonata Therapeutics (US) | |
Product | protein degradation drug | |
Product 2 | drug development | |
Record changed: 2022-06-28 |
Advertisement
More documents for Pearl S. Huang
- [1] Dunad Therapeutics. (6/28/22). "Press Release: Dunad Therapeutics Appoints Industry Veteran Pearl Huang as Chief Executive Officer". Cambridge....
- [2] Waters Corporation. (12/10/20). "Press Release: Waters Corporation Appoints Pearl S. Huang to Board of Directors". Milford, MA....
- [3] Flagship Pioneering. (10/8/19). "Press Release: Flagship Pioneering Unveils Cygnal Therapeutics. Company Is Developing Drugs in the Field of Exoneural Biology to Address Cancer, Inflammatory Disease, and More". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top